As of July 10, 2024, AMPYRA® (dalfampridine), INBRIJA® (levodopa inhalation powder) and ARCUS® technology have been acquired by Merz Therapeutics and will continue to be available to customers through Merz Therapeutics. Click here for more information.
Products
![](/assets/img/section-hero-image/products_mobile.jpg)
Bill Dollard
Employee since 2002
Technical Operations
As of July 10, 2024, AMPYRA® (dalfampridine), INBRIJA® (levodopa inhalation powder) and ARCUS® technology have been acquired by Merz Therapeutics and will continue to be available to customers through Merz Therapeutics. Click here for more information.